Mochida Pharmaceutical Co., Ltd.

Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. It offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatology, psychiatry, and gastroenterology, including Lialda, Omvoh, and Cortiment for the treatment of ulcerative colitis; Goofice and Movicol for the treatment of chronic constipation; Epadel for hyperlidemia and arteriosclerosis obliterans; Urece for gout and hyperuricemia; Treprost for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; Atelec, a calcium channel blocker; Dinagest, an agent for endometriosis, adenomyosis, and dysmenorrhea; Lexapro, an antidepressant; Tamcet, an analgesic for chronic pain; Beselna, a therapeutic agent for condyloma acuminatum and actinic keratosis; and Heparin Sodium MOCHIDA anticoagulant agents. The company also develops mesalazine for the treatment of ulcerative colitis; tocilizumab for the treatment of rheumatoid arthritis; dotinurad for the treatment of gout and hyperuricemia; dienogest formulation for dysmenorrhea; treprostinil for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and icosapent for hypertriglyceridemia. In addition, it develops medical devices, including dMD-001 that is used for the treatment of articular cartilage lesions; dMD-002, which is used for the treatment of cavernous nerve injury; and dMD-003 for post-operative adhesion. Further, the company engages in the development, production, distribution, sale, and marketing of skincare products. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.